Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Zomedica Stock Popped Today

By Joe Tenebruso – Oct 1, 2021 at 4:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors applauded the company's move to diversify its business.

What happened 

Shares of Zomedica (ZOM -1.08%) climbed on Friday after the animal health specialist struck a deal to acquire Pulse Veterinary Technologies. 

By the close of trading today, Zomedica's stock price was up 9.8% after rising as much as 21.2% earlier in the day.

So what

Pulse's electro-hydraulic shock wave technology has an array of veterinary applications, such as tendon, ligament, bone, and wound healing. It uses high-energy sound waves to stimulate cells and release healing growth factors in animals.

The all-cash transaction values Pulse at $70.9 million.

A veterinarian is holding an injured dog.

Image source: Getty Images.

Zomedica's management praised Pulse's razor-and-blades business strategy. In addition to the revenue the company earns from the initial sale of its shock wave generators, Pulse also generates recurring revenue from replaceable therapy handpieces.

"During our extensive due diligence process, we consistently were impressed by both the strength of the PulseVet team led by Adrian Lock and the solid business that they have built," Zomedica CEO Robert Cohen said in a press release. "We believe that this acquisition will enable us to enhance both of our organizations by what we learn from each other and add to the combined effort."

Now what

Zomedica said in May that it would use some of its $276.6 million in cash reserves to expand its product offerings beyond its Truforma diagnostics system for dogs and cats. The company's purchase of Pulse helps it do just that.

Zomedica intends to have its sales team market Pulse's new X-Trode handpiece, which does not require animals to be sedated, to accelerate its entrance into the veterinary market.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
ZOM
$0.20 (-1.08%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.